Pluto Bioinformatics

GSE147980: IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

Bulk RNA sequencing

We identified IGF2BP1 as a marker of the C5 molecular subtype of high-grade ovarian carcinoma (HG-SOC). IGF2BP1 promotes SRC activity and ERK2 expression enhancing the tolerance towards SRC- and MEK-directed inhibitors saracatinib and selumetib. Combination treatment overcomes IGF2BP1-promoted resistance. SOURCE: Danny Misiak ( - Hüttelmaier Lab Martin Luther University Halle-Wittenberg

View this experiment on Pluto Bioinformatics